These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 20542839

  • 1. Pediatric primary cutaneous marginal zone B-cell lymphoma treated with intralesional rituximab.
    Park MY, Jung HJ, Park JE, Kim YC.
    Eur J Dermatol; 2010; 20(4):533-4. PubMed ID: 20542839
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab.
    Kyrtsonis MC, Siakantaris MP, Kalpadakis C, Dimopoulou MN, Vassilakopoulos TP, Kontopidou FN, Antoniou C, Korkolopoulou P, Panayiotidis P, Pangalis GA.
    Eur J Haematol; 2006 Oct; 77(4):300-3. PubMed ID: 16856917
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Intralesional therapy with anti-CD20 monoclonal antibody rituximab: local and systemic efficacy in primary cutaneous B-cell lymphoma.
    Roguedas AM, Watier H, Paintaud G, de Muret A, Vaillant L, Machet L.
    Br J Dermatol; 2005 Mar; 152(3):541-4. PubMed ID: 15787825
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Eight-cycle rituximab therapy resulted in complete remission in primary cutaneous marginal zone lymphoma.
    Seker M, Ustaalioğlu BB, Bilici A, Yildirim ME, Kefeli U, Barisik NO, Tamer I, Gumus M.
    Leuk Res; 2010 Jul; 34(7):e160-3. PubMed ID: 20219245
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Treatment of radiation-relapsing primary cutaneous B-cell lymphoma with an anti-CD20 monoclonal antibody.
    Lacouture ME, Baron JM, Jani AB, Laumann AE, Soltani K.
    Clin Exp Dermatol; 2005 Jan; 30(1):46-8. PubMed ID: 15663503
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
    Gellrich S, Muche JM, Wilks A, Jasch KC, Voit C, Fischer T, Audring H, Sterry W.
    Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
    [Abstract] [Full Text] [Related]

  • 16. Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab.
    Morales AV, Advani R, Horwitz SM, Riaz N, Reddy S, Hoppe RT, Kim YH.
    J Am Acad Dermatol; 2008 Dec; 59(6):953-7. PubMed ID: 18817999
    [Abstract] [Full Text] [Related]

  • 17. Persistent CD20-negative primary cutaneous marginal zone lymphoma after treatment with intralesional rituximab therapy.
    Lozzi GP, Coletti G, Peris K.
    J Am Acad Dermatol; 2008 Nov; 59(5 Suppl):S110-2. PubMed ID: 19119114
    [No Abstract] [Full Text] [Related]

  • 18. Primary cutaneous B-cell lymphomas.
    Kempf W, Denisjuk N, Kerl K, Cozzio A, Sander C.
    J Dtsch Dermatol Ges; 2012 Jan; 10(1):12-22; quiz 23. PubMed ID: 22212142
    [Abstract] [Full Text] [Related]

  • 19. Complete remission of a primary cutaneous B-cell lymphoma of the lower leg by first-line monotherapy with the CD20-antibody rituximab.
    Bonnekoh B, Schulz M, Franke I, Gollnick H.
    J Cancer Res Clin Oncol; 2002 Mar; 128(3):161-6. PubMed ID: 11935303
    [Abstract] [Full Text] [Related]

  • 20. Regression of cutaneous intravascular lymphoma with rituximab.
    Han K, Haley JC, Carlson K, Pinter-Brown L, Soriano T.
    Cutis; 2003 Aug; 72(2):137-40. PubMed ID: 12953938
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.